Pretreatment of mice with rifampicin prolongs survival of endotoxic shock by modulating the levels of inflammatory cytokines

Immunopharmacology and Immunotoxicology

Volumn 30, Issue 3, 2008, Pages 437-446

  An, Na ^a   Song, Yu ^a   Zhang, Xuemei ^a   Ci, Xinxin ^a   Li, Hongyu ^a   Cao, Yongguo ^a   Zhang, Mohan ^a   Cui, Junqing ^b   Deng, Xuming ^a  

^a JILIN UNIVERSITY   (China)

^b PFIZER INC   (United States)

Author keywords

Cytokines; LPS; Mice; Rifampicin; Survival

Indexed keywords

CLINDAMYCIN; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 6; KETOLIDE; LIPOPOLYSACCHARIDE; MACROLIDE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; TELITHROMYCIN; TETRACYCLINE DERIVATIVE; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFICACY; FEMALE; GRAM NEGATIVE INFECTION; IMMUNOMODULATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; SEPTIC SHOCK; SURVIVAL; TREATMENT OUTCOME;

ANIMALS; ANTI-BACTERIAL AGENTS; CYTOKINES; DISEASE MODELS, ANIMAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; INFLAMMATION MEDIATORS; INTERLEUKIN-10; INTERLEUKIN-1BETA; INTERLEUKIN-6; LIPOPOLYSACCHARIDES; MICE; MICE, INBRED C57BL; RIFAMPIN; SHOCK, SEPTIC; TIME FACTORS; TUMOR NECROSIS FACTOR-ALPHA;

BACTERIA (MICROORGANISMS); MUS; NEGIBACTERIA;

EID: 48349138648     PISSN: 08923973     EISSN: 15322513     Source Type: Journal    
DOI: 10.1080/08923970802135146     Document Type: Article

References (21)

1. Cinel, I.; Dellinger, R.P. Advances in pathogenesis and management of sepsis. Curr. Opin. Infect. Dis. 2007, 20 (4), 345-352.
2. Ando, H.; Takamura, T.; Ota, T.; Nagai, Y.; Kobayashi, K. Cerivastatin improves survival of mice with lipopolysaccharide-induced sepsis. J. Pharmacol. Exp. Ther. 2000, 294 (3), 1043-1046.
3. Hirata, N.; Hiramatsu. K.; Kishi K.; Yamasaki, T.; Ichimiya, T.; Nasu, M. Pretreatment of mice with clindamycin improves survival of endotoxic shock by modulating the release of inflammatory cytokines. Antimicrob. Agents. Chemother. 2001, 45 (9), 2638-2642.
4. Leiva, M.; Ruiz-Bravo, A.; Moreno, E.; Jimenez-Valera, M. The anti-inflammatory activity of telithromycin in a mouse model of septic shock. Int. J. Antimicrob. Agents 2007, 29 (3), 364-5.
5. Ziglam, H.M.; Daniels, I.; Finch, R.G. Immunomodulatory activity of rifampicin. J. Chem. 2004, 16 (4), 357-61.
6. Richards, C.D.; Gauldie, J. Role of cytokines in acute-phase response. In: Human Cytokines: Their Role in Disease and Therapy, edited by Aggarwal, B.B.; and Puri, R.K. Cambridge, MA: Blackwell Science, 1995, p. 253-269.
7. Berg, D.J.; Kuhn, R.; Rajewsky, K.; Muller, W.; Menon, S.; Davidson, N.; Grunig, G.; Rennick, D. Interleukin-10 is a central regulator of the response to LPS in murine models of endotoxic shock and the Shwartzman reaction but not endotoxin tolerance. J. Clin. Invest. 1995, 96 (5), 2339-47.
8. Alexander, H.R.; Doherty, G.M.; Block, M.I.; Kragel, P.J.; Jensen, J.C.; Langstein, H.N.; Walker, E.; Norton, J.A. Single-dose tumor necrosis factor protection against endotoxin-induced shock and tissue injury in rats. Infect. Immune. 1991, 59 (11), 3889-3894.
9. Fraker, D.L.; Stovroff, M.C.; Merino M.J.; Norton, J.A. Tolerance to tumor necrosis factor in rats and the relationship to endotoxin tolerance and toxicity. J. Exp. Med. 1988, 168 (1), 95-105.
10. Purswani M.U.; Eckert, S.J.; Arora, H.K.; Noel, G.J. Effect of ciprofloxacin on lethal and sub lethal challenge with endotoxin and on early cytokine responses in a murine in vivo model. J. Antimicrob. Chemother. 2002, 50(1), 51-58.
11. Shapira, L.; Barak, V.; Soskolne, W.A.; Halabi, A.; Stabholz, A. Effect of tetracyclines on the pathologic activity of endotoxin: in vitro and vivo studies. Adv. Dent. Res. 1998, 12 (2), 119-122.
12. Tsuji, F.; Oki, K.; Okahara, A.; Suhara, H.; Yamanouchi, T.; Sasano, M.; Mita, S.; Horiuchi, M. Differential effects between marismastat, a TNF converting enzyme inhibitor, and anti-TNF antibody on murine models for sepsis and arthritis. Cytokine 2002, 17 (6), 294-300.
13. Mohler, K.M.; Torrance, D.S.; Smith, C.A.; Goodwin, R.G.; Stremler, K.E.; Fung, V.P.; Madani, H.; Widmer, M.B. Soluble tumor necrosis factor (TNF) receptors are effective therapeutic agents in lethal endotoxemia and function simultaneously as both TNF carriers and TNF antagonists. J Immunol. 1993, 151 (3), 1548-61.
14. Souza, D.G.; Ferreira, F.L.; Fagundes, C.T.; Amaral, F.A.; Vieira, A.T.; Lisboa, R.A.; Andrade, M.V.; Trifilieff, A.; Teixeira, M.M. Effects of PKF242-484 and PKF241-4g66, novel dual inhibitors of TNF-alpha converting enzyme and matrix metalloproteinases, in a model of intestinal reperfusion injury in mice. Eur. J. Pharmacol. 2007, 571 (1), 72-80.
15. Katsuno, G.; Takahashi, H.K.; Iwagaki, H.; Sugita, S.; Mori, S.; Saito, S.; Yoshino, T.; Nishibori, M.; Tanaka, N. The effect of ciprofloxacin on CD14 and toll-like receptor-4 expression on human monocytes. Shock 2006, 25 (3), 247-253.
16. Ali, A.; Pahlevan, D. J. M.; Wright, L. B.; Smith, C.; Foxwell, B.M.J. Potential of rifamides to inhibit TNF-induced NF-κB activation. J. Antimicrob. Chemother. 2002, 49 (3), 531-534.
17. Fiorentino, D.F.; Zlotnik, A.; Mosmamm, T.R.; Howard, M.; O'Garra, A. IL-10 inhibits cytokine production by activated macrophages. J. Immunol. 1991, 147 (11), 3815-3822.
18. Berg. D.J.; Kühn. R.; Rajewsky. K. Interleukin-10 is a central regulator of the response to LPS in murine models of endotoxic shock and the Schwartzman reaction but not endotoxin tolerance. J. Clin. Invest. 1995, 96 (5), 2339-2347.
19. Dinarello, C.A. The IL-1 family and inflammatory diseases. Clin. Exp. Rheumatol. 2002, 20 (27), 1-13.
20. Sakao, Y.; Takeda, K.; Tsutsui, H.; Kaisho, T.; Nomura, F.; Okamura, H.; Nakanishi, K.; Akira, S. IL-18-deficient mice are resistant to endotoxin-induced liver injury but highly susceptible to endotoxin shock. Internat. Immunol. 1999, 11 (3), 471-480.
21. Dinarello, C.A. Proinflammatory Cytokines. Chest. 2000, 118 (2), 503-508.